mAbs

Article	Citations
Tokenizing loops of antibodies	260
Correction	165
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	161
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	141
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	139
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	129
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	94
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	92
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	90
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	89
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	86
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	80
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	68
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	66
An antibody developability triaging pipeline exploiting protein language models	61
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma	60
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	55
Correction	55
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	51
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	51
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	50
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	48
Impact of IgG subclass on monoclonal antibody developability	45
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	45
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates	44

Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	43
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	43
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	40
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	38
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	38
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	37
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	35
Antibodies to watch in 2024	34
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	34
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	33
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG 1 antibody	32
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodies	32
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions	31
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO	30
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	29
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by k D, rheology, and Raman spectroscopy	29
Discovery of broadly neutralizing V H Hs against short-chain α-neurotoxins using a consensus toxin as an antigen	28
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	28
Quantifying antibody binding: techniques and therapeutic implications	28
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	28
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	27
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	27
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	27
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	26
Building a potent TREM2 agonistic, biparatopic, common light chain antibody	26
Correction	26
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab	26
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	26
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	25
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	24
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	24
Cost and supply considerations for antibody therapeutics	24
Antibodies to watch in 2026	24
Evolution of phage display libraries for therapeutic antibody discovery	24
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics	23
Electrostatic properties of human germlines and biodistribution of small biologics	23
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	23
A glyco-engineering approach for site-specific conjugation to Fab glycans	22
A versatile design platform for glycoengineering therapeutic antibodies	22
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	22
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	22
Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis	22
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	21
A comprehensive strategy for pandemic preparedness with neutralizing monoclonal antibodies	21
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	21
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	21
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	21
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	21
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A	20
Engineering death resistance in CHO cells for improved perfusion culture	20

Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	20
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	20
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	19
Leveraging multi-modal feature learning for predictions of antibody viscosity	19
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies	19
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	18
Predicting purification process fit of monoclonal antibodies using machine learning	18
Reduction of monoclonal antibody viscosity using interpretable machine learning	18
Multidimensional maturation of antibody variable domains with machine-learning assistance	18
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	18
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies	18
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	18
Structural and biochemical differences between non-catalytic and catalytic antibodies	18
Impact of process impurities on developability assessments of complex antibody formats: the striking role of leachable copper	18
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	17
Structure–function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody	16
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	16
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	16
Combining deep mutational scanning and SPR binning approaches for large-scale epitope identification of anti-ricin antibodies	16
Development of a PRAME pMHC targeted T cell engager for solid tumor therapy	16
Physics-based surface patch analysis for prediction of hydrophobic contribution to viscosity of mAbs	16
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	16
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	15
Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1	15
Alpseq : an open-source workflow to turbocharge nanobody discovery with high-throughput sequencing	15
Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy	14
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	14
Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	14
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	14
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	14
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity	13
2D NMR assessment of structural consistency and functional relationships in monoclonal antibodies	13
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	13
Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS	13
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows	13
Correction	13
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	13
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	13
A pH-sensitive binding modality allows successful transferrin receptor-mediated transcytosis of a bivalent antibody across brain barriers	12
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies	12
Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt	12
Engineering multispecific antibodies with complete killing selectivity through the closed-loop integration of machine learning and high-throughput experimentation	12
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations	12
A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization	12
Targeted fusion of antibody-secreting cells: Unlocking monoclonal antibody production with hybridoma technology	12
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy	12
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment	11
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releas	11
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases	11
Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations	11
Optimizing human FcRn mouse models to improve pharmacokinetic evaluation of antibody drug candidates	11
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties	11
Novel bispecific T-cell engagers overcoming acquired EGFR resistance	11
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age	11
Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity	11
Affinity-controlled capture and release of engineered monoclonal antibodies by macroporous dextran hydrogels using coiled-coil interactions	11
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy	11
A novel insulin-like growth factor II-based masking domain for conditional activation of therapeutic antibodies	11
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	10
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning	10
Correction	10
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies	10
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	10
Advanced cytokine-based immunotherapies: targeted cis-delivery strategies for enhanced anti-tumor efficacy and reduced toxicity	10
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	10
Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing	10
Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic	10
Systematic characterization of lysine glucuronidation in a bispecific antibody	10
Modulation of the high concentration viscosity of IgG 1 antibodies using clinically validated Fc mutations	10
Development of T-cell engagers selective for cells co-expressing two antigens	10
Achieving Acceleration to First-in-Human: MSD’s Learnings on Platform Method Validation Strategy	10
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy	10
Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease	10
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	9
Targeted dual selection to optimize transposon stable pool generation of multispecifics	9
Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody	9
Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery	9
Process development for production of non-originator NISTmAb from CHO and NS0 cell lines	9
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	9
Proceedings of the 15 th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals	9

Modular generation of multispecific antibodies using protein trans-splicing	9
Computational analysis reveals non-consensus N-glycosylation sequons in antibody Fab region	9
Characterization of free light chain impurity in a bispecific antibody	9
Molecular recognition requires dimerization of a VHH antibody	9
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques	9
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras	9
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors	9
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity	9
Successful targeting of multidrug-resistant tumors with bispecific antibodies	9
NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody–antigen interactions	9
Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAb	8
Beyond sequence similarity: ML-powered identification of pHLA off-targets for TCR-mimic antibodies using high throughput binding kinetics	8
Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity	8
Correction	8
A novel in vitro serum stability assay for antibody therapeutics incorporating internal standards	8
Use of poxvirus display to select antibodies specific for complex membrane antigens	8
A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia	8
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition	8
Bi-functional integrin degraders cause stronger anti-proliferative effects than a blocking antibody by modulating distinct downstream signaling	8
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	8
Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells	8
Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders	8
YAbS: The Antibody Society’s antibody therapeutics database	8
Fast-tracking antibody maturation using a B cell-based display system	8
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice	7
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans	7
Developing drug-like single-domain antibodies (VHH) from in vitro libraries	7
High-throughput small-angle X-ray scattering reveals effective structure factor transitions linked to high-concentration antibody viscosity	7
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life	7
Mechanistic insights into the rational design of masked antibodies	7
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice	7
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies	7
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain	7
Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold	7
Data-driven analyses of human antibody variable domain germlines: pairings, sequences and structural features	7
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET	7
AbDrop-a scalable microfluidics-enabled platform for rapid discovery and functional analysis of plasma cell-derived antibodies	7
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors	7
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	7
AbDesign: database of point mutants of antibodies with associated structures reveals poor generalization of binding predictions from machine learning models	7
Pharmacokinetic and biodistribution analysis of monoclonal antibodies: a comprehensive study of antibody biodistribution and partitioning coefficients in mice	7
Innovative strategies for T cell engagers for cancer immunotherapy	7
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	7
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper	7
Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies	6
How to think about designing smart antibodies in the age of genAI: integrating biology, technology, and experience	6
3C conjugates: a highly sensitive platform for antibody internalization assessment in ADC development	6
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations	6
Application of protein language models for antibody developability prediction	6
2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization	6
Optimizing asymmetric antibody purification: a semi-automated process and its digital integration	6
HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure	6
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy	6
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity	5
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models	5
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer	5
“Stapling” scFv for multispecific biotherapeutics of superior properties	5
Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study	5
Expanding the structural resolution of glycosylation microheterogeneity in therapeutic proteins by salt-free hydrophilic interaction liquid chromatography tandem mass spectrometry	5
AbDist: a lightweight, distance-based model for antibody affinity prediction as an interpretable benchmark for machine learning models	5
ASD: antigen-specific antibody database	5
Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation	5
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats	5
ManNAc attenuates Man5 glycoform abundance through GNE-mediated metabolic channeling of UDP-GlcNAc to N-glycosylation modifications via CMP-Neu5Ac biosynthesis	5
Development, qualification, and application of a highly efficient and robust new peak detection workflow for the LC-MS peptide mapping multi-attribute method	5
Trispecific SEED antibodies engineered for neutrophil-mediated cell killing	5
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration	5
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	5
Correction	5
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies	5
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	5
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies	5
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method	5
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT	5
Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring	5